Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to some targeted therapies for which dominant mechanisms of resistance have been observed, such as BCR-ABL mutations that cause resistance to imatinib in chronic myeloid leukemia,22 KRASG12C-mutant cancers appear to evolve diverse mechanisms of resistance to adagrasib.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [22]
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Items 1,001–1,008 of 1,008
Combination Therapies for the Optimisation of Bispecific T-Cell Engagers in Cancer Treatment
Zhu, W. M., & Middleton, M. R. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad013 · Cited by 46
“The ABL1 944C→T (Thr315Ile) mutation is a known driver of TKI resistance in haematological malignancies [50].”
Shee, K., Wells, J. D., Jiang, A., & Miller, T. W. (2019) · PLOS ONE · doi:10.1371/journal.pone.0224267 · Cited by 43
Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis
Jiang, S., Wang, X., He, Y., Huang, H., Cao, B., Zhang, Z., Liu, J., Wang, Q., Huang, Z., & Mao, X. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03732-6 · Cited by 35
Paradoxical activation of c-Src as a drug-resistant mechanism
Higuchi, M., Ishiyama, K., Maruoka, M., Kanamori, R., Takaori-Kondo, A., & Watanabe, N. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108876 · Cited by 31
Shi, P., Chandra, J., Sun, X., Gergely, M., Cortes, J. E., Garcia‐Manero, G., Arlinghaus, R. B., Lai, R., & Amin, H. M. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00795.x · Cited by 24
“The ability of IGF-IR inhibitor to overcome the resistance to imatinib was also illustrated when PPP caused marked decrease in the viability of BaF3 cells permanently transfected with BCR-ABL or BCR-ABL, two imatinibresistant BCR-ABL mutants that are known to have significant clinical impact in CML patients [23, 32, 3…”
BackgroundInfluentialThe Role of Preclinical Models in Radiopharmaceutical Therapy
Sgouros, G., Hobbs, R. F., & Abou, D. S. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e121 · Cited by 16
Hochhaus, A., Kim, D.-W., Cortes, J. E., Sasaki, K., Mauro, M. J., Hughes, T. P., Breccia, M., Talpaz, M., Minami, H., Goh, Y. T., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02578-7 · Cited by 14
“Resistance is frequently associated with emergent BCR::ABL1 kinase domain mutations, such as BCR::ABL1 T315I , in patients who may have limited available TKI options [2, 4, 18, 19].”
Investigational Janus kinase inhibitors in development for myelofibrosis
Bose, P., Abou Zahr, A., & Verstovsek, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323871 · Cited by 12
Metadata
- Authors
- Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Department of Pathology, and
- Department of Medicine,
- Corresponding author
- Sawyers, Charles L.
- Venue
- Science
- Published
- 2001-08-03
- Volume
- 293
- Issue
- 5531
- Pages
- 876-880
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999614615
- Cited by
- 3,104
- References
- 26
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 45 · 2023: 64 · 2022: 44 · 2021: 60 · 2020: 71 · 2019: 76 · 2018: 68 · 2017: 84 · 2016: 96 · 2015: 106 · 2014: 141 · 2013: 169 · 2012: 162
- FWCI
- 85.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- imatinib, BCR-ABL, chronic myeloid leukemia, drug resistance, Abl tyrosine kinase, BCR-ABL mutations, relapse
- MeSH terms
- Imatinib Mesylate, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Benzamides, Blast Crisis, Cell Line, Gene Amplification, Humans, Hydrogen Bonding, Molecular Sequence Data, Philadelphia Chromosome, Phosphorylation, Piperazines, Proto-Oncogene Proteins, Pyrimidines, Recurrence, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, abl, Proto-Oncogene Proteins c-abl, Point Mutation, Protein Structure, Tertiary, Drug Resistance, Neoplasm, Amino Acid Substitution, Proto-Oncogene Proteins c-crk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.